Anxiety, mood disorders and injection risk behaviors among cocaine users : results from the COSMO study by Roy, Élise et al.
1 
 
Title: Anxiety, mood disorders and injection risk behaviors among cocaine users: results 
from the COSMO study 
Authors: Élise RoyMD MSc1,2, Didier Jutras-Aswad MD MSc3,4, Karine Bertrand PhD1, Magali 
Dufour PhD1, Michel Perreault PhD5,6, Émélie Laverdière BSc1, Fabiola Bene-Tchaleu MSc1, 
Julie BruneauMD MSc3,7 
1Faculty of Medicine and Health Sciences, Université de Sherbrooke, Longueil, Québec, Canada. 
2Institut national de santé publique du Québec, Montréal, Québec, Canada. 3Research Center, 
Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, Québec Canada. 
4Department of Psychiatry, Université de Montréal, Montréal, Québec, Canada. 5Douglas Mental 
Health Institute, Montréal, Québec, Canada. 6Department of Psychiatry, McGill University, 
Montréal, Québec, Canada. 7Department of Family Medicine, Université de Montréal, Montréal, 
Québec, Canada 
Corresponding author: Élise Roy MD MSc 
Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Campus de Longueuil 
150 Place Charles-Le Moyne, room 200. Longueuil, Québec, Canada. J4K 0A8 
Tel : 450 463-1835 # 61823. Fax : 450 670-9016. Email : Elise.Roy@USherbrooke.ca  
Running head: Mental health and injection risk behaviors 
 Abstract: 250 words 
 Narrative: 3087 words  
 Number of Tables: 3 
 Number of Figures: 0 
 Number of References: 38 
2 
 
Abstract 
Background and Objectives: Despite being common among cocaine users, mental health 
problems and their relationship with HIV and hepatitis C high risk injection behaviors are poorly 
documented. This study was undertaken to examine the relationships between mood and anxiety 
disorders and the sharing of drug injection equipment among cocaine users who inject drugs.  
Methods: The sample was drawn from a prospective cohort study and comprises 387 
participants. The outcome of interest was "sharing injection material" in the past three months. 
The presence of mood and anxiety disorders during the past year was assessed using the CIDI 
questionnaire. Statistical analyses were conducted on baseline data using logistic regression.   
Results: Most participants were male (84.5%) and were aged 25 or over (92.2%); 43.0% 
qualified for an anxiety disorder diagnosis and 29.3% for a mood disorder diagnosis. Participants 
with anxiety disorders were more likely to share needles (Adjusted Odds Ratio (AOR): 2.13, 
95%CI: 1.15-3.96) and other injection material (AOR: 1.81, 95%CI: 1.12-2.92). No significant 
association was found between mood disorders and sharing behaviors. 
Discussion and Conclusions: Primary anxiety disorders but not mood disorders increases 
injection risk behaviors among cocaine users. These results bring to light another negative 
outcome of mental health comorbidity in this vulnerable population.  
Scientific Significance: This study underlines the need to fine-tune therapeutic approaches 
targeting specific mental health problems in individuals with cocaine use disorders. Longitudinal 
studies that assess impulsivity and other correlates of psychiatric disorders are needed to 
examine underlying mechanisms of high risk injection behaviors in comorbid populations. 
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Introduction 
 
Cocaine is one of the major illicit drugs used internationally. According to the World Drug 
Report (2013), cocaine use is on the rise in many regions of the world including Africa, Eastern 
Europe, Oceania and several parts of Asia.1 In North America and Western and Central Europe, 
over one percent of the adult population used cocaine in 2011. In Canada, consumption of 
cocaine in the past year varies greatly according to age, with prevalence of 2.7% for Canadians 
15 to 24 years old, and of 0.3% for 25 and older cohort in 2010.2  
 
Cocaine misuse is an important public health threat, especially when it comes to its role in the 
transmission of HIV and hepatitis C viruses (HCV).3-6 This phenomenon is of major concern in 
Canada where problematic cocaine use remains one of the main risk factors in stake in HIV and 
hepatitis C epidemics, primarily among people who inject drugs (PWID).7 In this regard, drug 
injection among cocaine users poses a significant challenge for harm reduction programs. 
Studies have shown that patterns of consumption are complex and dynamic among problematic 
cocaine users, particularly with respect to polysubstance use and routes of drug administration.8 
This significantly impacts risk taking behaviors which causes negative health outcomes among 
users. 
 
Overall, illicit drug use disorders are associated with a high prevalence of mental health 
disorders.9-12 Cocaine use disorders are specifically linked to increased prevalence of mood and 
anxiety disorders10 which in turn are associated with altered cognitive functions involved in 
decision-making and at-risk behaviors.13 Therefore, studying the relationships between mental 
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health problems and high-risk behaviors among cocaine users who inject drugs is of great 
clinical interest. Relatively few studies, mainly based on symptom assessment, have examined 
the relationship between mood and anxiety disorders and injection risk behaviors. Although 
studies often included cocaine users, none focused on this particular group.  
 
According to a meta-analysis on depression and substance-related behaviors among PWID,14 
most studies relied on clinical samples of opioid users, mainly conducted in methadone treatment 
settings. Only 13 out of the 55 identified studies examined sharing behaviors, mainly needle 
sharing. The results indicated a significant but weak association with depression. Only few 
observational studies have examined the relationship between depression and injection risk 
behaviors using measurement tools that allow diagnosis of psychiatric disorders. In Canada, a 
multisite study of street-based opiate users showed that those suffering from a diagnosis of 
depression were more likely to share injection equipment than those who did not.15 In the United 
States, a study conducted in Providence, Rhode Island, revealed that depression severity was 
associated with receptive needle sharing among PWID diagnosed with a depression.16 In 
contrast, a diagnosis of primary major depression was not found to be associated with injection 
risk behaviors among young PWID in Chicago, Illinois.17 
 
Inconsistent evidence exists regarding the relationship between anxiety and injection risk 
behaviors. In the United States, needle sharing was found positively associated with symptoms 
of increased anxiety18 and anxiety or tension.19 A positive association was also found between 
severity of anxious symptoms and several sharing behaviors including sharing needles, 
backloading, sharing filter/cookers, and sharing rinse water.20 Conversely, one recent study 
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showed a negative association between anxiety symptoms and needle sharing among PWID in 
India.21 Furthermore, in the young PWID study, although anxiety disorders were more prevalent 
among injectors who shared syringes, the association was not statistically significant.17  
 
The available data does not allow to estimate the magnitude of the relationship between mood 
and anxiety disorders and high risk injection practices among cocaine users. This gap in the 
literature hampers the ability of clinicians to accurately assess potential significant predisposing 
factors of at-risk injection behaviors. Such information could also pave way to more targeted 
preventive interventions. This study was thus carried out to estimate the prevalence of mood and 
anxiety disorders and their relationship with high risk injection behaviors among street-based 
cocaine users who were concomitantly injecting drugs. We hypothesized that both mood and 
anxiety disorders would be positively associated with injection risk behaviors in this population.  
 
The sample included in this analysis was drawn from a prospective cohort study of out-of-
treatment cocaine users initiated in Montréal, Canada, which the aim was to examine the 
relationship between HIV/HCV risk behaviors and mental health. Of the 605 cocaine users who 
were recruited in the cohort, 387 reported drug injection in the three months prior to baseline and 
formed the sample for this investigation. Age and gender distribution of both the full sample and 
the sample included in the analyses were similar with mean age being respectively 39.4 years 
(SD: 11.1) and 39.8 years (SD: 10.4) and gender distribution, 86.0% and 84.5% males. 
Compared to participants reporting injection, mean age and gender distribution of participants 
denying injection (n=218) were also similar (38.7 years; SD : 12.2 and 88.5% males), and there 
was no statistical difference. 
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Materials and Methods 
 
Baseline data was collected between October 2010 and April 2013. The methodology was 
described in detail elsewhere.22 To be eligible, participants needed to have used cocaine in the 
last month, either by smoking crack or by injection. They also had to speak French or English, be 
able to consent and be at least 14 years old. This research was approved by the ethical boards of 
the Faculty of medicine and health sciences of l’Université de Sherbrooke and the Centre 
Hospitalier de l’Université de Montréal.  
 
Study participants were, for the most part, recruited in community-based programs located in 
downtown Montréal, including homelessness day programs, shelters, and needle exchange 
programs. After providing informed consent, participants underwent an interviewer-administered 
questionnaire lasting between 60 and 90 minutes. Interviews were conducted in a research office 
located in this same neighbourhood as recruitment sites. Participants were offered a 30$ financial 
compensation for their time. For this investigation, we included only participants who reported 
drug injection in the three months prior to baseline. 
 
Measurements 
The outcome of interest for this study was “sharing injection material” in the past three months. 
Sharing injection material was defined as using injection paraphernalia that had already been 
used by someone else. These could be either needles or other injection materials. The sharing of 
other injection materials included i) the sharing of rinse or dilution water, cookers or filters, ii) 
backloading/frontloading (defined as sharing drug using a syringe that has already been used by 
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another person) and iii) “doing a wash” (defined as injecting drug residues extracted from a 
cotton, a filter or a container used by another person). The “life history calendar” technique was 
used to help situate participants in time in order to minimise recall bias.23 Recent life events were 
put on a visual calendar that was used to better define the time period assessed during the 
interview. 
 
The main independent variables for this study were the presence of mood and anxiety disorders 
during the past year. The World Mental Health Composite International Diagnostic Interview 
(CIDI) version 2.1 was used in assessing mood disorder diagnoses (major depression, bipolar 
disorders and dysthymia).24 The CIDIS developed by Kovess and colleagues was used to assess 
anxiety disorder diagnoses.25 Both instruments are well-validated tools that can be administered 
by lay interviewers and produce psychiatric diagnoses according to the fourth version of the 
Diagnostic and Statistical Manual of Mental Health Disorders published by the American 
Psychiatric Association.26 An inter-rater study of the CIDI has shown an excellent reliability with 
Kappa statistics of 0.9 and more for most diagnoses.27 Furthermore, using the CIDI and CIDIS  
allowed us to distinguish primary disorders from substance-induced disorders. The CIDI (for 
each symptom) and CIDIS are designed to assess whether disorders are primary or induced by 
substance use. Subjects are asked whether symptoms always occur as a result of medication, 
drugs or alcohol and if this is the case, then they do not qualify for the diagnosis. This approach 
reduces the chance of mental disorder overdiagnosis in drug using populations. At the same time, 
only drug users whose symptoms occur always when they consumed, disqualify themselves for 
the disorder diagnosis which allows the possibility of eliciting primary mental disorders among 
drug users. In the general population, while there was some initial concerns that the CIDI 
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strategy would lead to underestimate prevalence of psychiatric disorders, this has proved not to 
be the case.28  
 
Co-variables considered as potential confounders included age (younger than 25 years old versus 
older), gender, ethnicity (born in Canada versus outside), level of education (less than high 
school versus higher level), living with a partner, homelessness (defined as having lived or slept 
at least once in a shelter or in any place not intended for housing in the past 3 months), having an 
unstable income (defined as having a marginal or criminal source of income in the past 3 
months), reporting being HIV-antibody positive or HCV-antibody positive and level of 
dependence to cocaine using the severity of dependence scale (SDS).29 The SDS is a five items 
tool measuring the intensity of dependence to a drug over the past 3 months. The score ranges 
between 0 and 15. Cocaine dependence was determined by a SDS score of 4 or higher.30 
 
Analyses 
Proportions of participants who qualified for each category of psychiatric disorders, either mood 
or anxiety disorders, were calculated. Two series of univariate logistic regression analyses were 
conducted to assess the association between each disorder and other covariates and 1)“needle 
sharing” and 2) “sharing of injection material other than needle”. Two-tailed tests were used.  
Then, multivariate models considering all variables with a p-value ≤ 0.20 in univariate analyses, 
were carried out. Following the purposeful selection procedure, significant variables with a p-
value < 0.05 and those with a confounding effect were kept in the final models. A variable was 
considered confounding if its removal from the model changed a significant coefficient by more 
than 20%. Interactions between each psychiatric disorder and HIV or HCV self-report status 
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were also examined. Adjusted odds ratios (AOR) and 95% confidence intervals were derived 
from the final models. SPSS 18.0 and R 2.14.2 softwares were used to perform the analyses.  
 
 
Results 
 
The 387 participants who reported drug injection in the three months prior to baseline were 
mostly male (85.5%), aged 25 or older (92.2%) and born in Canada (96.6%) (table 1). Less than 
a fifth was living with a partner and two thirds had been homeless at least once in the past 3 
months. Almost half of the sample had less than a high school diploma and three quarters had 
relied at least once on marginal or criminal sources of income in the past three months. An HCV-
positive status was reported by 46.1%, while 17.4% reported being HIV-positive. More than half 
of participants had a high cocaine SDS score.  
 
In the three months prior to study entry, the vast majority of participants injected powder cocaine 
or crack cocaine (92.0%), followed by prescriptions opioids (55.6%), heroin (37.7%) and 
speedballs (a mixture of heroin and cocaine; 16.3%). Other injected substances included 
stimulants other than cocaine, such as amphetamines or methamphetamines (9.3%), 
psychotherapeutic medications (anxiolytics, hypnotics or antipsychotic; 5.4%), synthetic drugs 
(ecstasy, ketamine, GHB or hallucinogens; 5.2%) and two other prescription drugs (0.6%). 
Overall, 61% of participants injected at least two drugs. With respect to risk-taking behaviors, 
almost a third of participants had shared at least one injection material (including needles) in the 
past three months (29.5%). Sharing of cookers, needles and rinse or dilution water were the three 
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most common sharing practices. “Doing a wash”, sharing of filters and backloading/frontloading 
were reported by 10% or less of the sample. 
 
Mental health problems were frequent, with 43.0% of participants qualifying for anxiety 
disorders (phobic: 34.11%; panic: 17.45%; generalised anxiety: 16.93%) and 29.3% for mood 
disorders (major depression: 20.37%; bipolar: 8.09%; dysthymic : 3.39%). Results of univariate 
and multivariate logistic regression analyses are showed in Tables 2 and 3, respectively. Recent 
mood disorders were not associated to neither needle sharing or sharing of injection material 
other than needles during the past 3 months. However, in multivariate analyses, participants with 
recent anxiety disorders were more likely to share needles (AOR : 2.13, 95% CI : 1.15-3.96) and 
to share injection material other than needles (AOR : 1.81, 95% CI : 1.12-2.92) after adjusting 
for sociodemographic and serostatus co-variates.  
  
 
Discussion  
 
Participants to this study were all active cocaine users who were also injecting drugs. Using 
validated instruments, we were able to identify some of their primary mental disorders, which 
was one of our main objectives. We also examined the relationship between mood and anxiety 
disorders and high-risk injection behaviors.  
 
A diagnosis of recent mood disorder was found among 29.3% of participants whereas 43.0% had 
a diagnosis of recent anxiety disorders. There is much variability in the rates of mental disorders 
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reported among cocaine users in the literature. In a study carried out in a sample of cocaine users 
entering inpatient cocaine dependence treatment in Connecticut, 10% rates of recent mood and 
anxiety disorder diagnoses were documented using the Structured Clinical Interview for DSM 
Disorders.31 Among out of treatment cocaine users, using the DIS, a study conducted in St. 
Louis, Missouri, found that 10% of participants were suffering of major depression.32 In Spain, 
43% of young out-of-treatment cocaine users that were administered the CIDI had a lifetime 
mental disorder.33 The most common diagnosis was depression (37.5%) and a fifth of the sample 
had a recent mental disorder. These variations are probably due to methodological differences, 
including different diagnosis tools, recruitment strategies and study populations.  
 
Our study found that the presence of a mood disorder diagnosis was not significantly associated 
with injection risk behaviors among cocaine users who inject drugs. This finding is consistent 
with that of a recent study showing that there was no association between primary major 
depression and injection risk behaviors among young PWID in Chicago.17 It contrasts with the 
Canadian study that looked at the association between a diagnosis of depression and injection 
risk behaviors among street-based opiate users.15 In this latter study, participants suffering from 
major depression were more likely than users without depression to share injection equipment, 
either needles or other paraphernalia. Similarly, studies based on depressive symptoms 
assessment showed that severe depressive symptomatology was associated with a small increase 
in the probability of needle sharing.14,21,34,35 It was also the case for the sharing of cotton or 
cookers, but only among injectors with a co-occurrence of  high boredom.35 
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The absence of a correlation between sharing and a primary mood disorder diagnosis in our 
study raises the possibility that high risk behaviors could be better explained by mood 
symptomatology than by an actual mood disorder diagnosis among cocaine users who inject 
drugs. The neurobiological correlates of chronic cocaine exposure and those of depression are 
very similar, suggesting that there may be a number of common etiological factors for these two 
disorders.36 Furthermore, according to DSM-5, cocaine withdrawal is characterized by fatigue, 
change in appetite, dysphoria, sleep alteration, and psychomotor agitation or retardation, a 
syndrome that is very similar to depression, while many intoxication criteria mimic hypomania 
or mania (euphoria, tension, changes in sociability, psychomotor agitation). It is thus plausible 
that individuals with or without a diagnosis of primary mood disorders all show significant mood 
symptoms (with related neurobiological alterations) which, as reported in the literature, increase 
the risk of sharing behaviors. Unfortunately, we could not test this hypothesis within the current 
study. 
 
There is a dearth of research on the relationship between anxiety and injection risk behaviors 
among PWID not in treatment, and the few published studies available show contradictory 
results.19-21,37 Our results showed increased risk behaviors among PWID with a primary anxiety 
disorder, suggesting a specific contributions of anxiety that is not induced by substances. 
Anxiety symptoms induced by stimulants are often panic-like or similar to generalized anxiety, 
which thus can be observed in both users with and without a primary disorder. However, as 
opposed to mood disorders, specific symptoms linked to primary specific anxiety disorders (eg 
phobia) rarely occurs in the context of cocaine use alone. They could potentially explain the 
differences observed in our study among users with a diagnosis of primary anxiety disorders and 
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those without. Investigators have proposed several underlying mechanisms for the association 
between anxiety disorders and injection risk behaviors. Impulsivity, high tension or low self-
efficacy could be among the factors that jeopardize the capacity of drug injectors to have safe 
injection practices.16 Studies looking at the contribution and impact of each specific anxiety 
disorders may thus prove to be critical in order to truly address this research question.  
 
A major strength of this study is the accrual of a large sample of out-of-treatment chronic 
cocaine users who are often underrepresented in studies on mental health and injection risk 
behaviors. Another strength is that participants were administered a well-validated tool allowing 
for the assessment of mental disorder diagnoses in the context of an epidemiological study. Data 
collection by interview-administered questionnaires, using self-report information may have led 
to the minimization of certain stigmatized behaviors and a recall bias, which is a study limitation. 
Our study may not be generalized to other settings since female users accounted for only 15.5% 
of the sample. However these statistics are not surprising because they correspond to figures 
observed in other adult street-based populations in our region.38 Multicenter studies are needed to 
recruit sufficient numbers of street-based female cocaine users and achieve better representation 
of this vulnerable population. Finally, the cross-sectional design could not ascertain causality. 
The longitudinal follow-up of this cohort will help better understand the direction of the 
association, adding a temporal consideration to the analyses. 
 
 
Conclusion 
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The results of this study underline the need to fine-tune our therapeutic approaches targeting 
individuals with mental health problems and cocaine use disorders. It certainly challenges the 
common practice of “wait and see”, an approach that suggests to wait before intervening on 
anxiety because it is thought to be substance-induced until proven otherwise. On the contrary, 
our results suggest that interventions that decrease anxiety in cocaine dependent individuals 
should be developed to evaluate their ability to alleviate risky behaviors. Studies examining the 
specific chronology of anxiodepressive symptoms and risky behaviors could help to elucidate the 
main focus and timing of such potential new approaches. Exploring which neurobiological 
correlates of anxiodepressive symptoms and chronic cocaine exposure are involved and mediate 
the behaviors leading to risk-taking could also help to develop targeted intervention. Overall, the 
ability to conduct longitudinal studies that assess simultaneously multiple domains, correlates 
and dimensions of psychiatric disorders (e.g. biological markers, cognitive testing, personality 
traits) could be tremendously helpful to successfully move forward in understanding and 
addressing the destructive combination of substance use, mental health problems and risky 
behaviors.
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Table 1. Sociodemographic characteristics, serostatus, mental health disorders and drug injection 
material sharing of study participants at study entry (n=387).   
 n % 
Sociodemographic characteristics 
 Gender, female 60 15.5 
 Age ≥25 years old 357 92.2 
 Born outside Canada 13 3.4 
 Less than high school 186 48.1 
 Living with a partner† 60 15.5 
 Had ≥1x an unstable source of income† 284 73.4 
 Mainly homeless† 245 63.3 
Serostatus 
 Report an HIV-positive status a 67 17.4 
 Report an HCV-positive status b 177 46.1 
Mental health disorders 
 Anxiety disordersb‡ 165 43.0 
 Mood disordersc‡ 112 29.3 
Dependence to cocaine   
 High SDS score (≥4)b 224 58.3 
Drug injection material sharing  
 Needle sharinga† 58 15.0 
 Sharing of cookers a† 61 15.8 
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 Sharing of filters a† 35 9.1 
 Sharing of rinse or dilution water  a† 48 12.4 
 Backloading/ Frontloading a† 27 7.0 
 “Doing a wash” a† 39 10.1 
 Sharing of injection material other than needlesa†  95 24.6 
 Sharing of injection material including needlesa† 114 29.5 
a1 missing value, b3 missing values; c5 missing values; †Past 3 months; ‡Past 12 months. 
“Doing a wash”, injection drug residues extracted from a cotton, a filter or a container used by 
another person; sharing of injection material, injection material sharing including dilution water, 
cookers, filters, sharing while backloading/frontloading and “doing a wash”.  
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Table 2. Univariate logistic regression analyses of correlates of drug injection material 
sharing behaviors (n=387 ) 
 No  
n (%) 
Yes 
n (%) 
OR  
(95%CI) 
P* 
 Needle sharing, past 3 months 
Mood disorders‡ 96 (85.7) 16 (14.3) 0.93 (0.50 to 1.73) 0.812 
Anxiety disorders‡ 129 (78.2) 36 (21.8) 2.49 (1.40 to 4.42) 0.002 
Gender, female 45 (75.0) 15 (25.0) 2.19 (1.13 to 4.27) 0.019 
Age ≥25 years old 309 (86.6) 48 (13.4) 0.30 (0.13 to 0.67) 0.005† 
Born outside Canada 10 (76.9) 3 (23.1) 1.74 (0.46 to 6.50) 0.424† 
Less than high school 159 (85.9) 26 (14.1) 0.86 (0.49 to 1.51) 0.608 
Living with a partner 41 (68.3) 19 (31.7) 3.41 (1.80 to 6.46) <0.001 
Unstable source of income 237 (83.7) 46 (16.3) 1.47 (0.75 to 2.91) 0.263 
Homelessness 200 (82.0) 44 (18.0) 2.01 (1.06 to 3.82) 0.030 
Knowledge HIV-positive 
status 
50 (74.6) 17 (25.4) 2.36 (1.24 to 4.49) 0.007 
Knowledge HCV-positive 
status 
142 (80.2) 35 (19.8) 1.96 (1.11 to 3.47) 0.019 
High SDS score (≥4) 184 (82.1) 40 (17.9) 1.70 (0.94 to 3.10) 0.079 
 Sharing of injection material other than needle, past 3 
months 
Mood disorders‡ 83 (74.1) 29 (25.9) 1.08 (0.65 to 1.78) 0.780 
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Anxiety disorders‡ 112 (67.9) 53 (32.1) 1.98 (1.24 to 3.17) 0.004 
Gender, female 41 (68.3) 19 (31.7) 1.52 (0.84 to 2.78) 0.167 
Age ≥25 years old 275 (77.0) 82 (23.0) 0.37 (0.17 to 0.79) 0.009 
Born outside Canada 10 (76.9) 3 (23.1) 0.92 (0.25 to 3.40) >0.999† 
Less than high school 145 (78.4) 40 (21.6) 0.73 (0.46 to 1.17) 0.191 
Living with a partner 36 (60.0) 24 (40.0) 2.39 (1.34 to 4.28) 0.003 
Unstable source of income 206 (72.8) 77 (27.2) 1.77 (1.00 to 3.13) 0.050 
Homelessness 179 (73.4) 65 (26.6) 1.36 (0.83 to 2.22) 0.225 
Knowledge HIV-positive 
status 
47 (70.1) 20 (29.9) 1.40 (0.78 to 2.52) 0.254 
Knowledge HCV-positive 
status 
123 (69.5) 54 (30.5) 1.77 (1.11 to 2.82) 0.017 
High SDS score (≥4) 153 (68.3) 71 (31.7) 1.25 (0.80 to 1.96) 0.326 
*P-Value by Pearson chi-square test unless indicated otherwise; †P-Value by Fisher’s 
exact test. ‡Past 12 months. 
OR: Odd Ratio; CI: Confidence Interval. 
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Table 3. Multivariate logistic regression analyses of the association between material sharing 
outcomes and anxiety disorders, accounting for sociodemographic and serostatus co-variates.  
 
Needle sharing, past 3 months  
Sharing of injection material 
other than needle, past 3 
months 
 
 AOR 95% CI P  AOR 95% CI P  
Anxiety disorders† 2.13 1.15 to 3.96 0.017  1.81 1.12 to 2.92 0.016  
Age ≥25 years old 0.29 0.11 to 0.73 0.008  0.38 0.17 to 0.84 0.017  
Living with a partner 5.08 2.44 to 10.59 <0.001  2.31 1.27 to 4.18 0.006  
Homelessness 3.25 1.52 to 6.95 0.002   -   
Knowledge HIV-
positive status 
4.18 2.01 to 8.68 <0.001   -  
 
Knowledge HCV-
positive status 
 -   1.83 1.13 to 2.98 0.014 
 
Constant 0.08 - <0.001  0.39 - 0.024  
AOR: Adjusted Odd Ratio; CI: Confidence Interval. †Past 12 months 
 
